Pharmaceutical - Inflammatory diseases


Current filters:

Inflammatory diseases

Popular Filters

51 to 59 of 59 results

AstraZeneca collaborates with Amgen on five MAbs


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Amgen (Nasdaq: AMGN), the world's largest independent…

AmgenAnti-Arthritics/RheumaticsAstraZenecaBiotechnologybrodalumabInflammatory diseasesLicensingPharmaceutical

GSK exercises option for Galapagos drug candidates


Belgium-based Galapagos NV (Euronext: GLPG) says that its partner, UK pharma giant GlaxoSmithKline (LSE:…

Anti-Arthritics/RheumaticsBiotechnologyGalapagosGlaxoSmithKlineInflammatory diseasesLicensingPharmaceuticalResearch

Germany’s IQWiG finds no added benefit for Pfizer’s Xiapex


In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products…

EuropeInflammatory diseasesPfizerPharmaceuticalRegulationXiapex

Merck buys in Exelixis’ PI3K-Delta program; returns product to Acumen


California-based Exelixis (Nasdaq: EXEL) says it has granted US drug giant Merck & Co (NYSE: MRK) an…

Acumen PharmaceuticalsExelixisInflammatory diseasesLicensingMerck & CoNeurologicalOncologyPharmaceutical

BioLineRx inks deal with Compugen


Israeli biopharma company BioLineRx (TASE: BLRX) has entered into a collaboration with fellow Israel-based…

BioLineRxBiotechnologyCardio-vascularCompugenInflammatory diseasesLicensingOncologyPharmaceuticalResearch

New start-up TopiVert gets $12.5 million funding


UK investment group Imperial Innovations (AIM: IVO) and SV Life Sciences have committed to invest £8…

FinancialInflammatory diseasesJohnson & JohnsonPharmaceuticalResearchRespiVertTopiVert

Compugen links with DiscoveRx on novel peptide ligands for GPCR drug targets


Israel’s Compugen (Nasdaq: CGEN) and USA-based DiscoveRx have entered into a partnership for the…

Cardio-vascularCompugenDiscoveRxInflammatory diseasesPharmaceuticalResearch

Mundipharma commits over $50 million in R&D funding for Infinity’s PI3K inhibitor


Privately-held Mundipharma International as committed to providing over $50 million in funding in 2013…

FinancialInfinity PharmaceuticalsInflammatory diseasesLicensingMundi InternationalOncologyPharmaceuticalResearch

51 to 59 of 59 results

Back to top